EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 610 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Foodie Friday: Winter Warm-Up White Bean Soup February 11, 2022 Doctors Seem To Be Biased Against Unmarried Cancer Patients, Offer Them... November 26, 2019 Can Cancer Prevention Be Better Integrated into Primary Care? June 5, 2023 Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,... July 16, 2025 Load more HOT NEWS Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer Sharing Energy Help Desk for Oncologists Treating People with a Rare Leukemia Pays... Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto
